Menu
Shedding Light on the Risks
& Benefits of Medications
Shedding Light on the Risks
& Benefits of Medications FDA SIDE EFFECTS UPDATE: Testosterone Drugs and High Blood Pressure Risk
Safety updates sourced directly from the FDA's Drug Safety Database, presented in clear and accessible language
October 1, 2025
0 Comments
republishon this page:
Welcome to the FDA Side Effects Update. This series is designed to keep you informed about the latest safety advisories and newly documented side effects of your medications. In this installment, we’re highlighting safety updates concerning Androgel, Aveed, Azmiro, Jatenzo, Kyzatrex, Natesto, Testim, Tlando, Vogelxo, and Xyosted.
Side Effect Update for Testosterone Drugs
The medications included in this update are approved for adult males with conditions associated with a deficiency or absence of the male hormone testosterone. These conditions include primary hypogonadism, which occurs when the testes do not function properly, and secondary hypogonadism, which occurs when the problem originates in the pituitary gland. Symptoms of low testosterone, or “Low-T,” include reduced sex drive, erectile dysfunction, fatigue, and mood changes.
Testosterone-containing drugs that treat Low-T include topical gels, transdermal patches, buccal system (applied to upper gum or inner cheek), tablets, capsules and injections. Testosterone is a Class III controlled drug, due to its potential for abuse.
How to Read This Report
This report is prepared using the most recent information posted in the SrLC database. It highlights recent safety labeling changes. It includes only newly reported side effects and safety information; additional side effects and warnings will appear on the drug label. Not all recent changes to the SrLC database or the label may be listed here. For all changes and the complete list of warnings and side effects, please click on the drug label link.
Each of the items (approval and update dates, drug names, etc.) contained in this report are obtained from the SrLC. The side effects and medication descriptions are simplified and made clearer, if needed. Sometimes, additional sources, like a medical dictionary, may be used to translate technical medical phrases. Other sources (company news, FDA press releases, etc.) may be used to learn about some label changes.
These safety label updates were made in response to an FDA assessment of a clinical trial study called the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE). The study showed that the use of testosterone drugs did not increase the risk of death from cardiovascular causes more than placebo. The warning about major cardiovascular risks, which had been included on the labels since 2015, was removed in this update.
However, the TRAVERSE study also showed that participants taking testosterone experienced an increased incidence of venous thromboembolism (VTE), including deep vein thrombosis (DVT, a type of vein blockage caused by a blood clot in the leg) and pulmonary embolism (PE, a blockage caused by a blood clot in the lung). Warnings about VTE have been included on the labels since 2014. Updated safety information regarding VTE now includes the TRAVERSE clinical trials results and a warning in the patient counseling section.
Because the TRAVERSE study and additional ambulatory blood pressure (ABPM) studies showed an increased risk of developing high blood pressure among users of testosterone, a new warning about the risk of developing high blood pressure was also added.
Androgel (testosterone gel) 1% for topical use and 1.62% for topical use
Initial FDA Approval: 1953 (testosterone); this formulation was approved in 2000
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
FDA Safety Announcement: Androgel 1% FDA Safety Label Change and Revised Drug Label
Androgel 1.62% FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Aveed (testosterone undecanoate) injection, for intramuscular use
Initial FDA Approval: 1953 (testosterone); this formulation approved in 2014
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone. This medication is administered by a healthcare professional in a healthcare setting.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
Essential Extras: Aveed is available only through a restricted program called the Aveed REMS Program because of the risk of serious Pulmonary Oil Microembolism (POME) reactions and anaphylaxis during or immediately after receiving the injection. POME reactions involve the urge to cough, dyspnea, throat tightening, chest pain, dizziness, and fainting.
FDA Safety Announcement: Aveed FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Azmiro (testosterone cypionate) injection, solution for intramuscular use
Initial FDA Approval: 1953 (testosterone); this formulation approved in 2022
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
FDA Safety Announcement: Azmiro FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Jatenzo (testosterone undecanoate) capsules
Initial FDA Approval: 1953 (testosterone); this formulation approved in 2019
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
FDA Safety Announcement: Jatenzo FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Kyzatrex (testosterone undecanoate) capsules, liquid filled
Initial FDA Approval: 1953 (testosterone); this formulation approved in 2022
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
FDA Safety Announcement: Kyzatrex FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Natesto (testosterone) nasal gel
Initial FDA Approval: 1953 (testosterone); this formulation approved in 2014
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
FDA Safety Announcement: Natesto FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Testim (testosterone gel) for topical use
Initial FDA Approval: 1953 (testosterone); this formulation approved in 2002
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
FDA Safety Announcement: Testim FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Tlando (testosterone undecanoate) capsule, liquid filled
Initial FDA Approval: 1953 (testosterone); this formulation approved in 2022
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
FDA Safety Announcement: Tlando FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Vogelxo (testosterone) gel, for topical use
Initial FDA Approval: 1953 (testosterone); this formulation approved in 2014
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
FDA Safety Announcement: Vogelxo FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Xyosted (testosterone enanthate) autoinjector, subcutaneous
Initial FDA Approval: 1953 (testosterone); this formulation approved in 2018
Side Effect Update Date: July 11, 2025
Medication Description: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.
Updated Side Effect/Safety Information: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.
A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.
FDA Safety Announcement: Xyosted FDA Safety Label Change and Revised Drug Label
The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.
Want to Share Your Story?
If you’ve experienced side effects or medication issues related to this topic, we want to hear from you.
Submit Your Story- Research, C. F. D. E. A. (2025, February 28). FDA issues class-wide labeling changes for testosterone products. U.S. Food And Drug Administration.
- Research, C. F. D. E. A. (2025, February 28). Testosterone information. U.S. Food And Drug Administration.
- Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., Wang, Q., Wolski, K., Davey, D., Kalahasti, V., Khan, N., Miller, M. G., Snabes, M. C., Chan, A., Dubcenco, E., . . . Nissen, S. E. (2023). Cardiovascular safety of Testosterone-Replacement therapy. New England Journal of Medicine, 389(2), 107–117.
- What is venous thromboembolism? | NHLBI, NIH. (2022, September 19). NHLBI, NIH.
- Sizar, O., Leslie, S. W., & Schwartz, J. (2024, February 25). Male hypogonadism. StatPearls – NCBI Bookshelf.
- Hypogonadotropic hypogonadism: MedlinePlus Medical Encyclopedia. (n.d.).
- Approved Risk Evaluation and Mitigation Strategies (REMS). (n.d.). FDA.
DISCLAIMER: MedShadow provides information and resources related to medications, their effects, and potential side effects. However, it is important to note that we are not a substitute for professional medical advice, diagnosis, or treatment. The content on our site is intended for educational and informational purposes only. Individuals dealing with medical conditions or symptoms should seek guidance from a licensed healthcare professional, such as a physician or pharmacist, who can provide personalized medical advice tailored to their specific circumstances.
While we strive to ensure the accuracy and reliability of the information presented on MedShadow, we cannot guarantee its completeness or suitability for any particular individual’s medical needs. Therefore, we strongly encourage users to consult with qualified healthcare professionals regarding any health-related concerns or decisions. By accessing and using MedShadow, you acknowledge and agree that the information provided on the site is not a substitute for professional medical advice and that you should always consult with a qualified healthcare provider for any medical concerns.
on this page:
RECOMMENDED:
DONATE:
Help fund our fight for improved medication safety and transparency by supporting our independent journalism.
Give NowWe seek to create a world where there are safer medications for all and where all people are fully informed about their medication benefits and side effects, using our explanatory and investigative journalism to both inform and stimulate public discussion to drive toward solutions.
Republish This Story for Free
Creative Commons License (CC BY-NC-ND 4.0)MedShadow.org is dedicated to empowering people with our evidence-based journalism about the safest ways to take over-the-counter (OTC) and prescription (Rx) medications.
We also seek to stimulate public discussion about potential improvements to drug research, manufacturing and distribution processes. and also to encourage the improvement of processes to ensure that we are all better protected.
As a result, we encourage other nonprofit newsrooms, mission-aligned outlets, and advocacy organizations to republish our original content under the following conditions:
You May Republish Our Articles for Free If:
1. We Are Credited Fully and Clearly
You must include the byline and credit MedShadow.org as the original publisher. Please include a link to the original article at the top or bottom of the piece. Use the following attribution:
This article was originally published by MedShadow, a nonprofit foundation that focuses on the safest ways to take over-the-counter and prescription medications.
2. Our Content Isn’t Edited Without Permission
You may make small changes for clarity, such as adjusting headlines, subheadings, or transitions, but you may not change the core meaning, tone, or intent of the article. For substantive edits, email us at republish@medshadow.org for review and approval.
3. You Do Not Sell Or Use Our Content Commercially
Our work is free to share, but it may not be sold, monetized, or repurposed for commercial gain. You may not republish our articles behind a paywall or in publications whose primary purpose is advertising or product promotion. You may not place drug or supplement advertising adjacent to our story.
4. Photos, Graphics, and Multimedia Are Not Used Without Permission
Only the text of the article is available for republication. Images, graphics, and videos may not be reused without explicit written permission, unless they are clearly marked as Creative Commons licensed. Contact us if you’d like to request reuse of a visual asset.
You May Not:
- Use our content to promote a product, service, or political candidate
- Republish only part of an article or create derivative works without permission
- Add affiliate links, advertising overlays, or lead generators
- Translate the article without written permission
Contact Us
If you’re unsure whether your intended use falls within these guidelines, or would like to discuss a formal syndication or licensing arrangement, please email: republish@medshadow.org
We want our journalism to reach as many people as possible, especially those making critical decisions about medications and health.
Article HTML
<!-- wp:paragraph -->
<p>Welcome to the FDA Side Effects Update. This series is designed to keep you informed about the latest safety advisories and newly documented side effects of your medications. In this installment, we’re highlighting safety updates concerning Androgel, Aveed, Azmiro, Jatenzo, Kyzatrex, Natesto, Testim, Tlando, Vogelxo, and Xyosted.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":1} -->
<h1 class="wp-block-heading" id="h-side-effect-update-for-testosterone-drugs">Side Effect Update for Testosterone Drugs</h1>
<!-- /wp:heading --><!-- wp:paragraph -->
<p>The medications included in this update are approved for adult males with conditions associated with a deficiency or absence of the male hormone <a href="https://www.merriam-webster.com/dictionary/testosterone#medicalDictionary" target="_blank" rel="noreferrer noopener">testosterone</a>. These conditions include primary <a href="https://medlineplus.gov/ency/article/001195.htm" target="_blank" rel="noreferrer noopener">hypogonadism</a>, which occurs when the <a href="https://www.merriam-webster.com/dictionary/testes" target="_blank" rel="noreferrer noopener">testes</a> do not function properly, and secondary hypogonadism, which occurs when the problem originates in the <a href="https://www.merriam-webster.com/dictionary/pituitary%20gland" target="_blank" rel="noreferrer noopener">pituitary gland</a>. Symptoms of low testosterone, or “Low-T,” include reduced sex drive, erectile dysfunction, fatigue, and mood changes.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Testosterone-containing drugs that treat Low-T include topical gels, transdermal patches, buccal system (applied to upper gum or inner cheek), tablets, capsules and injections. Testosterone is a Class III controlled drug, due to its potential for abuse.</p>
<!-- /wp:paragraph --><!-- wp:myplugin/custom-alignment-block {"align":"right"} -->
<div class="wp-block-myplugin-custom-alignment-block alignright"><h2>How to Read This Report</h2><p>This report is prepared using the most recent information posted in the <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm" target="_blank" rel="noreferrer noopener">SrLC database</a>. It highlights recent safety labeling changes. It includes only newly reported side effects and safety information; additional side effects and warnings will appear on the drug label. Not all recent changes to the SrLC database or the label may be listed here. For all changes and the complete list of warnings and side effects, please click on the drug label link.<br><br>Each of the items (approval and update dates, drug names, etc.) contained in this report are obtained from the SrLC. The side effects and medication descriptions are simplified and made clearer, if needed. Sometimes, additional sources, like a medical dictionary, may be used to translate technical medical phrases. Other sources (company news, FDA press releases, etc.) may be used to learn about some label changes.</p></div>
<!-- /wp:myplugin/custom-alignment-block --><!-- wp:paragraph -->
<p>These safety label updates were made in response to an <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-issues-class-wide-labeling-changes-testosterone-products" target="_blank" rel="noreferrer noopener">FDA assessment</a> of a <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2215025" target="_blank" rel="noreferrer noopener">clinical trial study</a> called the Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men (TRAVERSE). The study showed that the use of testosterone drugs did not increase the risk of death from cardiovascular causes more than placebo. The warning about major cardiovascular risks, which had been included on the labels <a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022309Orig1s014ltr.pdf" target="_blank" rel="noreferrer noopener">since 2015</a>, was removed in this update.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>However, the TRAVERSE study also showed that participants taking testosterone experienced an increased incidence of <a href="https://www.nhlbi.nih.gov/health/venous-thromboembolism" target="_blank" rel="noreferrer noopener">venous thromboembolism</a> (VTE), including deep vein thrombosis (DVT, a type of vein blockage caused by a blood clot in the leg) and pulmonary embolism (PE, a blockage caused by a blood clot in the lung). Warnings about VTE have been included on the labels <a href="https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022309Orig1s012ltr.pdf" target="_blank" rel="noreferrer noopener">since 2014</a>. Updated safety information regarding VTE now includes the TRAVERSE clinical trials results and a warning in the patient counseling section.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>Because the TRAVERSE study and additional ambulatory blood pressure (ABPM) studies showed an increased risk of developing high blood pressure among users of testosterone, a new warning about the risk of developing high blood pressure was also added.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-androgel-testosterone-gel-1-for-topical-use-and-1-62-for-topical-use">Androgel (testosterone gel) 1% for topical use and 1.62% for topical use</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation was approved in 2000</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description:</strong> A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>:<a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=487" target="_blank" rel="noreferrer noopener"> Androgel 1% FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021015s047lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label<br></a><a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=486" target="_blank" rel="noreferrer noopener">Androgel 1.62% FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022309s022lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label<br></a>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-aveed-nbsp-testosterone-undecanoate-injection-for-intramuscular-use">Aveed (testosterone undecanoate) injection, for intramuscular use</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2014</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone. This medication is administered by a healthcare professional in a healthcare setting.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Essential Extras</strong>: Aveed is available only through a restricted program called the <a href="https://www.aveedrems.com/s/" target="_blank" rel="noreferrer noopener">Aveed REMS Program</a> because of the risk of serious Pulmonary Oil Microembolism (POME) reactions and anaphylaxis during or immediately after receiving the injection. POME reactions involve the urge to cough, dyspnea, throat tightening, chest pain, dizziness, and fainting.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=491" target="_blank" rel="noreferrer noopener">Aveed FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022219s021lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label<br></a>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-azmiro-testosterone-cypionate-injection-solution-for-intramuscular-use">Azmiro (testosterone cypionate) injection, solution for intramuscular use</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2022</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3153" target="_blank" rel="noreferrer noopener">Azmiro FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216318s005lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-jatenzo-testosterone-undecanoate-capsules">Jatenzo (testosterone undecanoate) capsules</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2019</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3158" target="_blank" rel="noreferrer noopener">Jatenzo FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/206089s009lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-kyzatrex-testosterone-undecanoate-capsules-liquid-filled">Kyzatrex (testosterone undecanoate) capsules, liquid filled</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2022</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3159" target="_blank" rel="noreferrer noopener">Kyzatrex FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/213953s005lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-natesto-testosterone-nasal-gel">Natesto (testosterone) nasal gel</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2014</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3159" target="_blank" rel="noreferrer noopener">Natesto FDA Safety Label Change</a> and<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/205488s005lbl.pdf" target="_blank" rel="noreferrer noopener"> Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-testim-testosterone-gel-for-topical-use">Testim (testosterone gel) for topical use</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2002</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=487" target="_blank" rel="noreferrer noopener">Testim FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021454s036lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-tlando-testosterone-undecanoate-capsule-liquid-filled">Tlando (testosterone undecanoate) capsule, liquid filled</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2022</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date:</strong> July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description:</strong> A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=3160" target="_blank" rel="noreferrer noopener">Tlando FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208088s002lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-vogelxo-testosterone-gel-for-topical-use">Vogelxo (testosterone) gel, for topical use</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2014</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=489" target="_blank" rel="noreferrer noopener">Vogelxo FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/204399s016lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph --><!-- wp:heading {"level":3} -->
<h3 class="wp-block-heading" id="h-xyosted-testosterone-enanthate-autoinjector-subcutaneous">Xyosted (testosterone enanthate) autoinjector, subcutaneous</h3>
<!-- /wp:heading --><!-- wp:paragraph -->
<p><strong>Initial FDA Approval</strong>: 1953 (testosterone); this formulation approved in 2018</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Side Effect Update Date</strong>: July 11, 2025</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Medication Description</strong>: A testosterone replacement therapy for adult males with conditions associated with a deficiency or absence of testosterone.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>Updated Side Effect/Safety Information</strong>: A new warning that testosterone can increase blood pressure, which can increase cardiovascular risk over time. Patients should measure blood pressure regularly. Testosterone is not recommended for use in men with uncontrolled hypertension.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>A warning that testosterone can cause venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Presents results of a recent clinical trial on testosterone and cardiac risks.</p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p><strong>FDA Safety Announcement</strong>: <a href="https://www.accessdata.fda.gov/scripts/cder/safetylabelingchanges/index.cfm?event=searchdetail.page&DrugNameID=2120" target="_blank" rel="noreferrer noopener">Xyosted FDA Safety Label Change</a> and <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209863s020lbl.pdf" target="_blank" rel="noreferrer noopener">Revised Drug Label</a></p>
<!-- /wp:paragraph --><!-- wp:paragraph -->
<p>The revised drug label contains a complete list of FDA-approved indications, side effects, warnings, and more.</p>
<!-- /wp:paragraph -->